Randy E. Dobbs, a director at Viemed Healthcare, Inc. (NASDAQ:VMD), recently sold 36,261 common shares of the company. The shares were sold at a price of $9.28 each, totaling $336,502. This sale follows an earlier exercise of stock options, where Dobbs acquired 36,261 shares at $1.81 per share, amounting to a total value of $65,632. Post-transaction, Dobbs holds 107,706 shares in the company. These transactions were reported in a recent SEC filing, providing insights into Dobbs' current holdings and recent activities with Viemed Healthcare stock.
In other recent news, Viemed Healthcare, Inc. reported a record-breaking third quarter in 2024, with net revenue reaching $58 million, surpassing their own guidance. This success is attributed to organic expansion and strategic mergers and acquisitions, with the company's active vent patient count increasing by 4.3%, and sleep therapy patient count rising by 11% sequentially. The company invested $11 million in CapEx, mainly for respiratory equipment, and anticipates Q4 net revenue to be between $59.7 million and $60.9 million.
Despite challenges in replacing a significant fleet of recalled ventilators, which may affect CapEx into the next year, Viemed remains optimistic about future growth. In the recent earnings call, COO Todd Zehnder indicated a robust pipeline and openness to deals outside the respiratory space. The company is also collaborating with Philips and the FDA for the remediation of recalled ventilators. These are among the recent developments at Viemed Healthcare, Inc.
InvestingPro Insights
To provide additional context to Randy E. Dobbs' recent stock transactions, it's worth examining some key financial metrics and insights from InvestingPro regarding Viemed Healthcare, Inc. (NASDAQ:VMD).
According to InvestingPro data, Viemed Healthcare has a market capitalization of $356.66 million USD. The company's P/E ratio stands at 34.01, which aligns with an InvestingPro Tip indicating that VMD is "trading at a high earnings multiple." This valuation metric suggests that investors have high expectations for the company's future growth.
Viemed's revenue growth is noteworthy, with a 26.22% increase in the last twelve months as of Q3 2024. This strong performance is reflected in the stock's recent market performance, as another InvestingPro Tip highlights a "strong return over the last three months." Indeed, the 3-month price total return stands at an impressive 32.58%.
The company's financial health appears solid, with an InvestingPro Tip noting that "cash flows can sufficiently cover interest payments" and that VMD "operates with a moderate level of debt." This financial stability may provide reassurance to investors considering the recent insider sale.
For those interested in a more comprehensive analysis, InvestingPro offers 7 additional tips for Viemed Healthcare, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.